Characterization of Defects in Ion Transport and Tissue Development in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)-Knockout Rats
Year: 2014
Type: article
Abstract: Animal models for cystic fibrosis (CF) have contributed significantly to our understanding of disease pathogenesis. Here we describe development and characterization of the first cystic fibrosis rat, in which the cystic fibrosis transmembrane conductance regulator gene (CFTR) was knocked out using a pair of zinc finger endonucleases (ZFN). The disrupted Cftr gene carries a 16 base pair deletion in exon 3, resulting in loss of CFTR protein expression. Breeding of heterozygous (CFTR+/-) rats resulted in Mendelian distribution of wild-type, heterozygous, and homozygous (CFTR-/-) pups. Nasal potential difference and transepithelial short circuit current measurements established a robust CF bioelectric phenotype, similar in many respects to that seen in CF patients. Young CFTR-/- rats exhibited histological abnormalities in the ileum and increased intracellular mucus in the proximal nasal septa. By six weeks of age, CFTR-/- males lacked the vas deferens bilaterally. Airway surface liquid and periciliary liquid depth were reduced, and submucosal gland size was abnormal in CFTR-/- animals. Use of ZFN based gene disruption successfully generated a CF animal model that recapitulates many aspects of human disease, and may be useful for modeling other CF genotypes, including CFTR processing defects, premature truncation alleles, and channel gating abnormalities.
Source: PLoS ONE
Authors: Katherine L. Tuggle, Susan E. Birket, Xiaoxia Cui, Jeong Hong, Joe Warren, Lara Reid, Andre Chambers, Diana Ji, Kevin Gamber, Kengyeh K. Chu, Guillermo Tearney, Li Ping Tang, James A. Fortenberry, Ming Du, Joan M. Cadillac, David M. Bedwell, Steven M. Rowe, Eric J. Sorscher, Michelle V. Fanucchi
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,382
Funders: Cystic Fibrosis Foundation, American Lung Association, Pfizer, Gilead Sciences, Cystic Fibrosis Foundation Therapeutics, Vertex Pharmaceuticals, PTC Therapeutics, Samsung Advanced Institute of Technology, Bayer HealthCare, Terumo, National Institutes of Health, Samsung, National Heart, Lung, and Blood Institute, National Institute of Diabetes and Digestive and Kidney Diseases
OpenAlex ID: W2106552432
